Latest & greatest articles for omeprazole

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on omeprazole or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on omeprazole and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for omeprazole

1. Omeprazole

Omeprazole Top results for omeprazole - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for omeprazole The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

2. Effect of clopidogrel on the hydroxylation and sulfoxidation of omeprazole: A single dose study in healthy human volunteers

Effect of clopidogrel on the hydroxylation and sulfoxidation of omeprazole: A single dose study in healthy human volunteers 28507476 2018 11 13 1611-2156 16 2017 EXCLI journal EXCLI J Effect of clopidogrel on the hydroxylation and sulfoxidation of omeprazole: A single dose study in healthy human volunteers. 321-327 10.17179/excli2016-658 Based upon the known potential interaction between omeprazole (OMP) and clopidogrel (CLOP), the current study was designed to evaluate the effect of CLOP (...) on disposition of OMP and its two major metabolites, 5-hydroxyomeprazole (5-OH-OMP) and omeprazole sulfone (OMP-S) in healthy clinical subjects. A randomized, open label, 2-period, crossover study was designed. Twelve volunteers were selected, of whom eight were extensive metabolizers (EM) of CYP2C19 and 4 were poor metabolizers (PM). They received single dose of OMP either alone or in combination with CLOP (single dose) and samples were collected periodically to calculate various pharmacokinetic parameters

EXCLI journal2017 Full Text: Link to full Text with Trip Pro

3. Annals of Internal Medicine Article The Effect of Endoscopic Therapy in Patients Receiving Omeprazole for Bleeding Ulcers with Nonbleeding Visible Vessels or Adherent Clots

Annals of Internal Medicine Article The Effect of Endoscopic Therapy in Patients Receiving Omeprazole for Bleeding Ulcers with Nonbleeding Visible Vessels or Adherent Clots Annals of Internal Medicine Artic... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 2003 ) Volume: 139 , Issue: 11 , Pages: 237-244 ISSN: 15393704 PubMed: Available from or Find this paper at: Abstract The optimal

Annals of Internal Medicine2013

4. A randomized controlled study comparing omeprazole and cimetidine for the prophylaxis of stress-related upper gastrointestinal bleeding in patients with intracerebral hemorrhage

A randomized controlled study comparing omeprazole and cimetidine for the prophylaxis of stress-related upper gastrointestinal bleeding in patients with intracerebral hemorrhage 23061387 2013 01 02 2013 03 12 2013 11 21 1933-0693 118 1 2013 Jan Journal of neurosurgery J. Neurosurg. A randomized controlled study comparing omeprazole and cimetidine for the prophylaxis of stress-related upper gastrointestinal bleeding in patients with intracerebral hemorrhage. 115-20 10.3171/2012.9.JNS12170 (...) Patients with intracerebral hemorrhage (ICH) are at high risk for severe stress-related upper gastrointestinal (UGI) bleeding, which is predictive of higher mortality. The aim of this study was to evaluate the effectiveness of omeprazole and cimetidine compared with a placebo in the prevention and management of stress-related UGI bleeding in patients with ICH. In a single-center, randomized, placebo-controlled study, 184 surgically treated patients with CT-proven ICH within 72 hours of ictus

EvidenceUpdates2013

5. Randomized controlled trial of standard versus high-dose intravenous omeprazole after endoscopic therapy in high-risk patients with acute peptic ulcer bleeding.

Randomized controlled trial of standard versus high-dose intravenous omeprazole after endoscopic therapy in high-risk patients with acute peptic ulcer bleeding. 21305536 2011 04 04 2011 06 06 2014 11 20 1365-2168 98 5 2011 May The British journal of surgery Br J Surg Randomized controlled trial of standard versus high-dose intravenous omeprazole after endoscopic therapy in high-risk patients with acute peptic ulcer bleeding. 640-4 10.1002/bjs.7420 Rebleeding from peptic ulcers is a major (...) contributor to death. This study compared standard (40-mg intravenous infusion of omeprazole once daily for 3 days) and high-dose (80-mg bolus of omeprazole followed by 8-mg/h infusion for 72 h) in reducing the rebleeding rate (primary endpoint), need for surgery, duration of hospital stay and mortality in patients with peptic ulcer bleeding after successful endoscopic therapy. This was a single-institution prospective randomized controlled study based on a postulated therapeutic equivalence of the two

EvidenceUpdates2011

6. Randomised controlled trial: Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding

Randomised controlled trial: Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Addition of omeprazole to dual antiplatelet therapy with clopidogrel plus aspirin lowers the risk of upper gastrointestinal bleeding Article Text Therapeutics Randomised controlled trial Addition of omeprazole to dual

Evidence-Based Medicine (Requires free registration)2011

7. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.

Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. 21345487 2011 03 14 2011 03 31 2015 06 16 1474-547X 377 9769 2011 Mar 12 Lancet (London, England) Lancet Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus (...) in 39 sites in Europe, comparing the efficacy and safety of 10 days of quadruple therapy with omeprazole plus a single three-in-one capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline (quadruple therapy) versus 7 days of omeprazole, amoxicillin, and clarithromycin (standard therapy) in adults with recorded H pylori infection. Patients were randomly assigned treatment according to a predetermined list independently generated by Quintiles Canada (Ville St-Laurent, QC

Lancet2011

8. Interaction of clopidogrel and omeprazole.

Interaction of clopidogrel and omeprazole. Interaction of clopidogrel and omeprazole. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 21067412 Format MeSH and Other Data E-mail Subject Additional text E-mail (...) Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2010 Nov 11;363(20):1977. doi: 10.1056/NEJMc1012022. Interaction of clopidogrel and omeprazole. , . Comment on [N Engl J Med. 2010] PMID: 21067412 DOI: [Indexed for MEDLINE] Free full text Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments How to cite this comment: Supplemental Content Full

NEJM2010

10. Clopidogrel with or without omeprazole in coronary artery disease.

Clopidogrel with or without omeprazole in coronary artery disease. 20925534 2010 11 11 2010 11 30 2013 11 21 1533-4406 363 20 2010 Nov 11 The New England journal of medicine N. Engl. J. Med. Clopidogrel with or without omeprazole in coronary artery disease. 1909-17 10.1056/NEJMoa1007964 Gastrointestinal complications are an important problem of antithrombotic therapy. Proton-pump inhibitors (PPIs) are believed to decrease the risk of such complications, though no randomized trial has proved (...) this in patients receiving dual antiplatelet therapy. Recently, concerns have been raised about the potential for PPIs to blunt the efficacy of clopidogrel. We randomly assigned patients with an indication for dual antiplatelet therapy to receive clopidogrel in combination with either omeprazole or placebo, in addition to aspirin. The primary gastrointestinal end point was a composite of overt or occult bleeding, symptomatic gastroduodenal ulcers or erosions, obstruction, or perforation. The primary

NEJM2010

11. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.

Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. 20638563 2010 07 19 2010 07 29 2015 11 19 1474-547X 376 9736 2010 Jul 17 Lancet (London, England) Lancet Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. 173-9 10.1016/S0140-6736(10)60673-3 Cyclo-oxygenase (COX)-2-selective non-steroidal anti-inflammatory drugs (NSAIDs) and non-selective (...) NSAIDs plus a proton-pump inhibitor (PPI) have similar upper gastrointestinal outcomes, but risk of clinical outcomes across the entire gastrointestinal tract might be lower with selective drugs than with non-selective drugs. We aimed to compare risk of gastrointestinal events associated with celecoxib versus diclofenac slow release plus omeprazole. We undertook a 6-month, double-blind, randomised trial in patients with osteoarthritis or rheumatoid arthritis at increased gastrointestinal risk at 196

Lancet2010

12. Use of intravenous omeprazole in gastrointestinal patients before endoscopy

Use of intravenous omeprazole in gastrointestinal patients before endoscopy BestBets: Use of intravenous omeprazole in gastrointestinal patients before endoscopy Use of intravenous omeprazole in gastrointestinal patients before endoscopy Report By: CK TAI - Resident Search checked by Colin A Graham - Professor Institution: Prince of Wales Hospital, Hong Kong Date Submitted: 26th May 2008 Last Modified: 29th October 2008 Status: Green (complete) Three Part Question Does [intravenous omeprazole (...) ] lead to [a decrease in the rebleeding rate] for [patients with suspected gastrointestinal bleeding in the emergency department]? Clinical Scenario A 55 year-old woman presents to the emergency department with fresh malaena. She is haemodynamically unstable. You wonder whether early use of intravenous omeprazole (prior to endoscopy) could reduce her rebleeding rate after emergency upper gastrointestinal endoscopy. Search Strategy Medline searched from 1997 to May week 1 2008 using the OVID interface

BestBETS2008

13. Cost-effectiveness analysis of high-dose omeprazole infusion before endoscopy for patients with upper-GI bleeding

Cost-effectiveness analysis of high-dose omeprazole infusion before endoscopy for patients with upper-GI bleeding Cost-effectiveness analysis of high-dose omeprazole infusion before endoscopy for patients with upper-GI bleeding Cost-effectiveness analysis of high-dose omeprazole infusion before endoscopy for patients with upper-GI bleeding Tsoi KK, Lau JY, Sung JJ Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) of the effectiveness data, overall, the methodology was valid. The conclusions reached by the authors appear to be appropriate and reflect the limited scope of their analysis. Type of economic evaluation Cost-effectiveness analysis Study objective The objective was to estimate the cost-effectiveness of using a proton-pump inhibitor (PPI) before an endoscopy for the management of upper-gastrointestinal bleeding. Interventions The intervention was omeprazole (a PPI) at a dose of 80mg as an intravenous injection

NHS Economic Evaluation Database.2008

14. Omeprazole before endoscopy in patients with gastrointestinal bleeding.

Omeprazole before endoscopy in patients with gastrointestinal bleeding. 17442905 2007 04 19 2007 04 24 2014 11 20 1533-4406 356 16 2007 Apr 19 The New England journal of medicine N. Engl. J. Med. Omeprazole before endoscopy in patients with gastrointestinal bleeding. 1631-40 A neutral gastric pH is critical for the stability of clots over bleeding arteries. We investigated the effect of preemptive infusion of omeprazole before endoscopy on the need for endoscopic therapy. Consecutive patients (...) admitted with upper gastrointestinal bleeding underwent stabilization and were then randomly assigned to receive either omeprazole or placebo (each as an 80-mg intravenous bolus followed by an 8-mg infusion per hour) before endoscopy the next morning. Over a 17-month period, 638 patients were enrolled and randomly assigned to omeprazole or placebo (319 in each group). The need for endoscopic treatment was lower in the omeprazole group than in the placebo group (60 of the 314 patients included

NEJM2007

15. A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study

A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study (...) Veldhuyzen van Zanten S J, Chiba N, Armstrong D, Barkun A, Thomson A, Smyth S, Escobedo S, Lee J, Sinclair P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared omeprazole (20 mg once daily), ranitidine (150 mg twice

NHS Economic Evaluation Database.2005

16. Cost-effectiveness analysis of high-dose omeprazole infusion as adjuvant therapy to endoscopic treatment of bleeding peptic ulcer

Cost-effectiveness analysis of high-dose omeprazole infusion as adjuvant therapy to endoscopic treatment of bleeding peptic ulcer Cost-effectiveness analysis of high-dose omeprazole infusion as adjuvant therapy to endoscopic treatment of bleeding peptic ulcer Cost-effectiveness analysis of high-dose omeprazole infusion as adjuvant therapy to endoscopic treatment of bleeding peptic ulcer Lee K K, You J H, Wong I C, Kwong S K, Lau J M, Chan T Y, Lau J T, Leung W Y, Sung J J, Chung S S Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The intravenous (i.v.) administration of a high-dose proton-pump inhibitor (PPI), namely omeprazole, after the endoscopic treatment of bleeding peptic ulcers. The dosage considered was bolus

NHS Economic Evaluation Database.2003

17. Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment.

Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment. 12763982 2003 05 23 2003 06 16 2014 06 11 1756-1833 326 7399 2003 May 24 BMJ (Clinical research ed.) BMJ Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment. 1118 To compare the efficacy of a "Helicobacter pylori test and treat" strategy with that of an empirical trial of omeprazole in the non-endoscopic management (...) by empirical prescribing of young patients with dyspepsia. Randomised controlled trial. Hospital gastroenterology unit. 219 patients under 45 years old presenting with dyspepsia without alarm symptoms. Patients received treatment with omeprazole 20 mg (group A) or with a urea breath test followed by an eradication treatment in case of H pylori infection or omeprazole alone in non-infected patients (group B). Lack of improvement or recurrence of symptoms prompted endoscopy. Improvement in symptoms assessed

BMJ2003 Full Text: Link to full Text with Trip Pro

18. Cost-effectiveness analysis of proton pump inhibitors compared to omeprazole in the healing of reflux oesophagitis

Cost-effectiveness analysis of proton pump inhibitors compared to omeprazole in the healing of reflux oesophagitis Cost-effectiveness analysis of proton pump inhibitors compared to omeprazole in the healing of reflux oesophagitis Cost-effectiveness analysis of proton pump inhibitors compared to omeprazole in the healing of reflux oesophagitis Plumb J M, Edwards S J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) review were the relative risk (RR) for healing with esomeprazole, lansoprazole, pantoprazole and rabeprazole relative to omeprazole at 4 and 8 weeks. These RR values were then converted into probability values ("calculated" healing rates) used in the decision model. The additional healing rates at 8 weeks, if not healed at 4 weeks, were also derived from the systematic review. Study designs and other criteria for inclusion in the review Not reported. Sources searched to identify primary studies

NHS Economic Evaluation Database.2002

19. Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies

Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand (...) esomeprazole with conventional omeprazole strategies Wahlqvist P, Junghard O, Higgins A, Green J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three strategies for the treatment of patients with gastro-oesophageal reflux disease (GORD

NHS Economic Evaluation Database.2002

20. Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK

Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK Wahlqvist P, Junghard O, Higgins A, Green J Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health interventions examined in the study were esomeprazole (40 mg once daily) and omeprazole (20 mg once daily) for the acute treatment of reflux oesophagitis. Type of intervention Treatment. Economic study type Cost-effectiveness analysis

NHS Economic Evaluation Database.2002